<?xml version="1.0"?>
<Articles JournalTitle="Acta Medica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>57</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2019</Year>
        <Month>02</Month>
        <Day>13</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Effect of N-Acetylcysteine on Inflammatory and Biochemical Markers of Hemodialysis Patients: A Randomized Controlled Trial</title>
    <FirstPage>57</FirstPage>
    <LastPage>62</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Rozina</FirstName>
        <LastName>Abasi Larki</LastName>
        <affiliation locale="en_US">Department of Nephrology, Yasuj University of Medical Sciences, Yasuj, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Alireza</FirstName>
        <LastName>Panahi</LastName>
        <affiliation locale="en_US">Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Leila</FirstName>
        <LastName>Manzouri</LastName>
        <affiliation locale="en_US">Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Moslem</FirstName>
        <LastName>Sedaghattalab</LastName>
        <affiliation locale="en_US">Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2018</Year>
        <Month>02</Month>
        <Day>09</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2018</Year>
        <Month>12</Month>
        <Day>15</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">The oxidative stress results in atherosclerosis and cardiovascular diseases in patients receiving hemodialysis. N-acetylcysteine is a well-known antioxidant agent. There are little studies about the effect of N-acetylcysteine on patients receiving hemodialysis, and, if any, their results are inconsistent. This study, as a double-blind, randomized clinical trial, was conducted on 44 hemodialysis patients in Shahid Beheshti Hospital, Yasuj, Iran in 2015. Patients were randomly allocated into two groups, in the intervention group, N-acetylcysteine 600 mg every 12 hours for eight weeks was administered and the second group received placebo during this period every 12 hours. Blood samples were taken to measure C-reactive protein, interleukin-6 and other biochemical markers such as ferritin, albumin, and creatinine at baseline and at the end of treatment. 40 patients completed the study (21 on N-acetylcysteine, 19 on placebo), with a mean age of 60.72&#xB1;17.60. There was not any significant difference between intervention and control groups in interleukin-6 (8.85&#xB1;6.9 vs. 10.32&#xB1;8.68, 95% CI, -3.52 to 6.46; P=0.55) and C - reactive protein (0.85&#xB1;0.29 vs. 0.9&#xB1;0.31, 95% CI, -.14 to .24; P=0.60). In addition, there was no significant relationship between the two groups in other biochemical markers. In this study, administering N-acetylcysteine was safe and caused a reduction in some inflammatory markers, but these changes were not significant in comparison with placebo.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/7035</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/7035/5210</pdf_url>
  </Article>
</Articles>
